JP2024507991A5 - - Google Patents

Info

Publication number
JP2024507991A5
JP2024507991A5 JP2023552197A JP2023552197A JP2024507991A5 JP 2024507991 A5 JP2024507991 A5 JP 2024507991A5 JP 2023552197 A JP2023552197 A JP 2023552197A JP 2023552197 A JP2023552197 A JP 2023552197A JP 2024507991 A5 JP2024507991 A5 JP 2024507991A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
dosage form
acceptable salt
combination
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017963 external-priority patent/WO2022183029A1/en
Publication of JP2024507991A publication Critical patent/JP2024507991A/ja
Publication of JP2024507991A5 publication Critical patent/JP2024507991A5/ja
Pending legal-status Critical Current

Links

JP2023552197A 2021-02-26 2022-02-25 激越を処置するための方法及び組成物 Pending JP2024507991A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154281P 2021-02-26 2021-02-26
US63/154,281 2021-02-26
PCT/US2022/017963 WO2022183029A1 (en) 2021-02-26 2022-02-25 Methods and compositions for treating agitation

Publications (2)

Publication Number Publication Date
JP2024507991A JP2024507991A (ja) 2024-02-21
JP2024507991A5 true JP2024507991A5 (cg-RX-API-DMAC7.html) 2025-03-03

Family

ID=83048476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552197A Pending JP2024507991A (ja) 2021-02-26 2022-02-25 激越を処置するための方法及び組成物

Country Status (7)

Country Link
US (2) US20240139169A1 (cg-RX-API-DMAC7.html)
EP (1) EP4297871A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024507991A (cg-RX-API-DMAC7.html)
CN (1) CN117412747A (cg-RX-API-DMAC7.html)
CA (1) CA3208828A1 (cg-RX-API-DMAC7.html)
TW (1) TW202302094A (cg-RX-API-DMAC7.html)
WO (1) WO2022183029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
AU2020407163A1 (en) * 2019-12-16 2022-07-21 Minute Molecular Diagnostics, Inc. Lyophilized reagents
EP4580619A1 (en) * 2022-08-31 2025-07-09 BioXcel Therapeutics, Inc. Methods and compositions for treating acute stress disorder
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024211911A1 (en) * 2023-04-07 2024-10-10 Oaktree Fund Administration, Llc Methods for treating depressive states
WO2024263973A1 (en) * 2023-06-23 2024-12-26 Bioxcel Therapeutics, Inc. Dexmedetomidine treatment regimens

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
WO2007041697A2 (en) * 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2420235A1 (en) * 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
CA2719824A1 (en) * 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
NO2200610T3 (cg-RX-API-DMAC7.html) * 2007-09-21 2018-06-09
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2010031054A1 (en) * 2008-09-15 2010-03-18 Biovista, Inc. Compositions and methods for treating epilepsy
TR200903014A1 (tr) * 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan dimebolin bileşimleri.
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
JP6013364B2 (ja) * 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルapiローディングプロドラッグ
WO2013114400A2 (en) * 2012-01-20 2013-08-08 Rubicon Research Private Limited Compressed pharmaceutical compositions of atypical antipsychotics
PL2774991T3 (pl) * 2013-03-06 2018-05-30 Life Science Inkubator Betriebs Gmbh & Co. Kg System dostarczania leków do stosowania w leczeniu lub diagnostyce zaburzeń neurologicznych
CN104530413B (zh) * 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
WO2016061554A1 (en) * 2014-10-16 2016-04-21 Bioxcel Corporation Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
IL267689B2 (en) * 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
IL279713B2 (en) * 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
EP3999058A4 (en) * 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
JP2023545372A (ja) * 2020-10-08 2023-10-30 バイオエクセル セラピューティクス,インコーポレイテッド デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療

Similar Documents

Publication Publication Date Title
US9782403B2 (en) Treating sexual desire disorders with flibanserin
JP6491174B2 (ja) ニタゾキサニドの制御放出医薬配合物
JP5553452B2 (ja) ブリバラセタムを含む医薬組成物
EP3417861B1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
CN101384545B (zh) 氘化的儿茶酚胺衍生物及包含所述化合物的药物
AU2011290614B2 (en) Nalbuphine-based formulations and uses thereof
JP2023551427A (ja) 口腔粘膜送達のための急速注入組成物及び方法
EP2921170A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
TW200900094A (en) Solid preparation
JP7137850B2 (ja) バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤
JPH08505379A (ja) パーキンソン病およびパーキンソン病症候群の治療のためのカルバマゼピンおよびオキカルバゼピンの用途
MXPA06012116A (es) Uso de flibanserina en el tratamiento del trastornos premestruales y otros trastornos sexuales femeninos.
JP2007508336A5 (cg-RX-API-DMAC7.html)
US11779559B2 (en) Compositions for treating fungal and bacterial biofilms and methods of using the same
JP2020523335A5 (cg-RX-API-DMAC7.html)
EP2496217B1 (en) Direct compression tablets of otilonium
CN117412747A (zh) 用于治疗激越的方法和组合物
JP2022504181A5 (cg-RX-API-DMAC7.html)
CN111065384A (zh) 扑热息痛的口腔崩解膜组合物
CN116036079B (zh) 一种复合物的药物组合物及其制备方法
ZA200409237B (en) Immediate release pharmaceutical formulation.
WO2021261837A1 (ko) 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물
ES2617657T3 (es) Derivado de metastina y uso del mismo
WO2018062685A1 (ko) 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제
CN1112929C (zh) 含有咪唑拉汀的缓释药物制剂